{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:13:51Z","timestamp":1780413231899,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00059-026-05375-9","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:14:24Z","timestamp":1775578464000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kardiovaskul\u00e4re Pharmakotherapie im Zeitalter RNA-basierter Pr\u00e4zisionsmedizin","Cardiovascular pharmacotherapy in the era of RNA-based precision medicine"],"prefix":"10.1007","volume":"51","author":[{"given":"Anselm A.","family":"Derda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hohneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"5375_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"5375_CR2","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J Qual Care Clin Outcomes 44:3627\u20133639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"5375_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine 381:1995\u20132008. https:\/\/doi.org\/10.1056\/nejmoa1911303","journal-title":"New England Journal of Medicine"},{"key":"5375_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine 383:1413\u20131424. https:\/\/doi.org\/10.1056\/nejmoa2022190","journal-title":"New England Journal of Medicine"},{"key":"5375_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs\u00a0J (2021) Heart failure drug treatment: the fantastic four. Eur Heart J Qual Care Clin Outcomes 42:681\u2013683. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1012","journal-title":"Eur Heart J"},{"key":"5375_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa\u00a0A, Davison\u00a0B, Chioncel\u00a0O et\u00a0al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet 400:1938\u20131952. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1","journal-title":"The Lancet"},{"key":"5375_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene\u00a0SJ, Butler\u00a0J, Albert\u00a0NM et\u00a0al (2018) Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. JACC Adv 72:351\u2013366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"key":"5375_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","volume":"11","author":"G Savarese","year":"2023","unstructured":"Savarese\u00a0G, Kishi\u00a0T, Vardeny\u00a0O et\u00a0al (2023) Heart Failure Drug Treatment\u2014Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail 11:1\u201314. https:\/\/doi.org\/10.1016\/j.jchf.2022.08.009","journal-title":"JACC Heart Fail"},{"key":"5375_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/nejmoa2415471","volume":"393","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek\u00a0U, Gro\u00dfhennig\u00a0A, Schwab\u00a0J et\u00a0al (2025) Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine 393:1155\u20131165. https:\/\/doi.org\/10.1056\/nejmoa2415471","journal-title":"New England Journal of Medicine"},{"key":"5375_CR10","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ejhf.3428","volume":"26","author":"DJ van Veldhuisen","year":"2024","unstructured":"van Veldhuisen\u00a0DJ, Rienstra\u00a0M, Mosterd\u00a0A et\u00a0al (2024) Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial. ESC Heart Fail 26:2223\u20132230. https:\/\/doi.org\/10.1002\/ejhf.3428","journal-title":"Eur J Heart Fail"},{"key":"5375_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt\u00a0B, Zannad\u00a0F, Remme\u00a0WJ et\u00a0al (1999) The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine 341:709\u2013717. https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"New England Journal of Medicine"},{"key":"5375_CR12","volume-title":"The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction","author":"B Pitt","year":"2001","unstructured":"Pitt\u00a0B, Williams\u00a0G, Remme\u00a0W et\u00a0al (2001) The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction. Kluwer Academic Publishers"},{"key":"5375_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad\u00a0F, McMurray\u00a0JJV, Krum\u00a0H et\u00a0al (2011) Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine 364:11\u201321. https:\/\/doi.org\/10.1056\/nejmoa1009492","journal-title":"New England Journal of Medicine"},{"key":"5375_CR14","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine 383:2219\u20132229. https:\/\/doi.org\/10.1056\/nejmoa2025845","journal-title":"New England Journal of Medicine"},{"key":"5375_CR15","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, Filippatos\u00a0G, Agarwal\u00a0R et\u00a0al (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine 385:2252\u20132263. https:\/\/doi.org\/10.1056\/nejmoa2110956","journal-title":"New England Journal of Medicine"},{"key":"5375_CR16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/nejmoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Vaduganathan\u00a0M et\u00a0al (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine 391:1475\u20131485. https:\/\/doi.org\/10.1056\/nejmoa2407107","journal-title":"New England Journal of Medicine"},{"key":"5375_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et\u00a0al (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine 385:1451\u20131461. https:\/\/doi.org\/10.1056\/nejmoa2107038","journal-title":"New England Journal of Medicine"},{"key":"5375_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/nejmoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Claggett\u00a0B et\u00a0al (2022) Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine 387:1089\u20131098. https:\/\/doi.org\/10.1056\/nejmoa2206286","journal-title":"New England Journal of Medicine"},{"key":"5375_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/nejmoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0MN, Abildstr\u00f8m\u00a0SZ, Borlaug\u00a0BA et\u00a0al (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine 389:1069\u20131084. https:\/\/doi.org\/10.1056\/nejmoa2306963","journal-title":"New England Journal of Medicine"},{"key":"5375_CR20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/nejmoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod\u00a0MN, Petrie\u00a0MC, Borlaug\u00a0BA et\u00a0al (2024) Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine 390:1394\u20131407. https:\/\/doi.org\/10.1056\/nejmoa2313917","journal-title":"New England Journal of Medicine"},{"key":"5375_CR21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/nejmoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, Bain\u00a0SC, Consoli\u00a0A et\u00a0al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 375:1834\u20131844. https:\/\/doi.org\/10.1056\/nejmoa1607141","journal-title":"New England Journal of Medicine"},{"key":"5375_CR22","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/nejmoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM, Brown-Frandsen\u00a0K, Colhoun\u00a0HM et\u00a0al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine 389:2221\u20132232. https:\/\/doi.org\/10.1056\/nejmoa2307563","journal-title":"New England Journal of Medicine"},{"key":"5375_CR23","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","volume":"29","author":"JM ter Maaten","year":"2023","unstructured":"ter Maaten\u00a0JM, Beldhuis\u00a0IE, van der Meer\u00a0P et\u00a0al (2023) Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med 29:2625\u20132632. https:\/\/doi.org\/10.1038\/s41591-023-02532-z","journal-title":"Nat Med"},{"key":"5375_CR24","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"ESC","year":"2014","unstructured":"ESC (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J Qual Care Clin Outcomes 35:2733\u20132779. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284","journal-title":"Eur Heart J"},{"key":"5375_CR25","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","volume":"83","author":"SR Ommen","year":"2024","unstructured":"Ommen\u00a0SR, Ho\u00a0CY, Asif\u00a0IM et\u00a0al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy. JACC Adv 83:2324\u20132405. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.014","journal-title":"JACC"},{"key":"5375_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1403422","author":"AA Derda","year":"2024","unstructured":"Derda\u00a0AA, Abelmann\u00a0M, Sonnenschein\u00a0K et\u00a0al (2024) Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2024.1403422","journal-title":"Front Cardiovasc Med"},{"key":"5375_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto\u00a0I, Oreziak\u00a0A, Barriales-Villa\u00a0R et\u00a0al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 396:759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","journal-title":"The Lancet"},{"key":"5375_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader\u00a0F, Or\u0119ziak\u00a0A, Choudhury\u00a0L et\u00a0al (2024) Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC Heart Fail 12:164\u2013177. https:\/\/doi.org\/10.1016\/j.jchf.2023.09.028","journal-title":"JACC Heart Fail"},{"key":"5375_CR29","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/nejmoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron\u00a0MS, Masri\u00a0A, Nassif\u00a0ME et\u00a0al (2024) Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine 390:1849\u20131861. https:\/\/doi.org\/10.1056\/nejmoa2401424","journal-title":"New England Journal of Medicine"},{"key":"5375_CR30","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/nejmoa2505927","volume":"393","author":"MY Desai","year":"2025","unstructured":"Desai\u00a0MY, Owens\u00a0AT, Abraham\u00a0T et\u00a0al (2025) Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine 393:961\u2013972. https:\/\/doi.org\/10.1056\/nejmoa2505927","journal-title":"New England Journal of Medicine"},{"key":"5375_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","volume":"30","author":"A MASRI","year":"2024","unstructured":"MASRI\u00a0A, SHERRID\u00a0MV, ABRAHAM\u00a0TP et\u00a0al (2024) Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J\u00a0Card Fail 30:1439\u20131448. https:\/\/doi.org\/10.1016\/j.cardfail.2024.02.020","journal-title":"J Card Fail"},{"key":"5375_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4244\/EIJ-D-22-01006","volume":"19","author":"G Tarantini","year":"2023","unstructured":"Tarantini\u00a0G, Smits\u00a0PC, Lhermusier\u00a0T et\u00a0al (2023) A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial. EuroIntervention 19:240\u2013247. https:\/\/doi.org\/10.4244\/EIJ-D-22-01006","journal-title":"EuroIntervention"},{"key":"5375_CR33","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/nejmoa2507980","volume":"393","author":"PO Guimar\u00e3es","year":"2025","unstructured":"Guimar\u00e3es\u00a0PO, Franken\u00a0M, Tavares\u00a0CAM et\u00a0al (2025) Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. New England Journal of Medicine 393:2095\u20132106. https:\/\/doi.org\/10.1056\/nejmoa2507980","journal-title":"New England Journal of Medicine"},{"key":"5375_CR34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini\u00a0JP, Caso\u00a0V, Connolly\u00a0SJ et\u00a0al (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet 399:1383\u20131390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1","journal-title":"The Lancet"},{"key":"5375_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma\u00a0M, Molina\u00a0CA, Toyoda\u00a0K et\u00a0al (2024) Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 23:46\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(23)00403-9","journal-title":"Lancet Neurol"},{"key":"5375_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/esj\/aakaf017","author":"M Sharma","year":"2026","unstructured":"Sharma\u00a0M, Dong\u00a0Q, Hirano\u00a0T et\u00a0al (2026) Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention. Eur Stroke J. https:\/\/doi.org\/10.1093\/esj\/aakaf017","journal-title":"Eur Stroke J"},{"key":"5375_CR37","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/nejmoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen\u00a0SE, Lincoff\u00a0AM, Brennan\u00a0D et\u00a0al (2023) Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine 388:1353\u20131364. https:\/\/doi.org\/10.1056\/nejmoa2215024","journal-title":"New England Journal of Medicine"},{"key":"5375_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, Daniels\u00a0GH, Brown-Frandsen\u00a0K et\u00a0al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"New England Journal of Medicine"},{"key":"5375_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02105-1","author":"MA Nauck","year":"2026","unstructured":"Nauck\u00a0MA, Tuttle\u00a0KR, Tsch\u00f6p\u00a0MH, Bl\u00fcher\u00a0M (2026) Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(25)02105-1","journal-title":"The Lancet"},{"key":"5375_CR40","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/nejmoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls\u00a0SJ, Pavo\u00a0I, Bhatt\u00a0DL et\u00a0al (2025) Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine 393:2409\u20132420. https:\/\/doi.org\/10.1056\/nejmoa2505928","journal-title":"New England Journal of Medicine"},{"key":"5375_CR41","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/nejmoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine\u00a0MS, Giugliano\u00a0RP, Keech\u00a0AC et\u00a0al (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine 376:1713\u20131722. https:\/\/doi.org\/10.1056\/nejmoa1615664","journal-title":"New England Journal of Medicine"},{"key":"5375_CR42","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/nejmoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz\u00a0GG, Steg\u00a0PG, Szarek\u00a0M et\u00a0al (2018) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine 379:2097\u20132107. https:\/\/doi.org\/10.1056\/nejmoa1801174","journal-title":"New England Journal of Medicine"},{"key":"5375_CR43","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/nejmoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray\u00a0KK, Wright\u00a0RS, Kallend\u00a0D et\u00a0al (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine 382:1507\u20131519. https:\/\/doi.org\/10.1056\/nejmoa1912387","journal-title":"New England Journal of Medicine"},{"key":"5375_CR44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12325-025-03418-x","volume":"43","author":"W Masson","year":"2026","unstructured":"Masson\u00a0W, Lobo\u00a0M, Giunta\u00a0G et\u00a0al (2026) Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. Adv Ther 43:304\u2013316. https:\/\/doi.org\/10.1007\/s12325-025-03418-x","journal-title":"Adv Ther"},{"key":"5375_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","volume":"12","author":"MJ Koren","year":"2024","unstructured":"Koren\u00a0MJ, Descamps\u00a0O, Hata\u00a0Y et\u00a0al (2024) PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial. Lancet Diabetes Endocrinol 12:174\u2013183. https:\/\/doi.org\/10.1016\/S2213-8587(23)00325-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5375_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/nejmoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas\u00a0S, Karwatowska-Prokopczuk\u00a0E, Gouni-Berthold\u00a0I et\u00a0al (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine 382:244\u2013255. https:\/\/doi.org\/10.1056\/nejmoa1905239","journal-title":"New England Journal of Medicine"},{"key":"5375_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","volume":"287","author":"L Cho","year":"2025","unstructured":"Cho\u00a0L, Nicholls\u00a0SJ, Nordestgaard\u00a0BG et\u00a0al (2025) Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). Am Heart J 287:1\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2025.03.019","journal-title":"Am Heart J"},{"key":"5375_CR48","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue\u00a0ML, Rosenson\u00a0RS, Gencer\u00a0B et\u00a0al (2022) Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. New England Journal of Medicine 387:1855\u20131864. https:\/\/doi.org\/10.1056\/NEJMoa2211023","journal-title":"New England Journal of Medicine"},{"key":"5375_CR49","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen\u00a0SE, Wang\u00a0Q, Nicholls\u00a0SJ et\u00a0al (2024) Zerlasiran - A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA 332:1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957","journal-title":"JAMA"},{"key":"5375_CR50","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/nejmoa2415818","volume":"392","author":"SE Nissen","year":"2025","unstructured":"Nissen\u00a0SE, Ni\u00a0W, Shen\u00a0X et\u00a0al (2025) Lepodisiran \u2014 A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). New England Journal of Medicine 392:1673\u20131683. https:\/\/doi.org\/10.1056\/nejmoa2415818","journal-title":"New England Journal of Medicine"},{"key":"5375_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai\u00a0AS, Webb\u00a0DJ, Taubel\u00a0J et\u00a0al (2023) Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. New England Journal of Medicine 389:228\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa2208391","journal-title":"New England Journal of Medicine"},{"key":"5375_CR52","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack\u00a0JM, Azizi\u00a0M, Brown\u00a0JM et\u00a0al (2025) Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. New England Journal of Medicine 393:1363\u20131374. https:\/\/doi.org\/10.1056\/NEJMoa2507109","journal-title":"New England Journal of Medicine"},{"key":"5375_CR53","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin\u00a0LJ, Kopjar\u00a0B, Melgaard\u00a0C et\u00a0al (2025) Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. New England Journal of Medicine 392:1813\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa2501440","journal-title":"New England Journal of Medicine"},{"key":"5375_CR54","doi-asserted-by":"crossref","unstructured":"Lee RC, Feinbaum RL, Ambrost V (1993) The C. elegans Heterochronic Gene lin\u20114 Encodes Small RNAs with Antisense Complementarity to &II-14","DOI":"10.1016\/0092-8674(93)90529-Y"},{"key":"5375_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","volume":"75","author":"B Wightman","year":"1993","unstructured":"Wightman\u00a0B, Ha\u00a0I, Ruvkun\u00a0G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin\u20114 mediates temporal pattern formation in C. elegans. Cell 75:855\u2013862. https:\/\/doi.org\/10.1016\/0092-8674(93)90530-4","journal-title":"Cell"},{"key":"5375_CR56","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2021","unstructured":"T\u00e4ubel\u00a0J, Hauke\u00a0W, Rump\u00a0S et\u00a0al (2021) Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J Qual Care Clin Outcomes 42:178\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa898","journal-title":"Eur Heart J"},{"key":"5375_CR57","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2021","unstructured":"T\u00e4ubel\u00a0J, Hauke\u00a0W, Rump\u00a0S et\u00a0al (2021) Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J Qual Care Clin Outcomes 42:178\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa898","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-026-05375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-026-05375-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-026-05375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:45:07Z","timestamp":1780411507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-026-05375-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5375"],"URL":"https:\/\/doi.org\/10.1007\/s00059-026-05375-9","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"A.A.\u00a0Derda\n                      erhielt Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeiten von AstraZeneca, Bayer, BNK, Boehringer Ingelheim Pharma GmbH, Bristol-Myers Squibb, Eli Lilly Company, DGK-Akademie. Es bestehen keine Besch\u00e4ftigungsverh\u00e4ltnisse zu gewinnorientierten oder gemeinn\u00fctzigen Organisationen.\n                      A.\u00a0Hohneck\n                      erhielt Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeiten von AMGEN, AstraZeneca, Bayer Vital GmbH, Boehringer Ingelheim Pharma GmbH, Daiichi-Sanky\u014d, DGK-Akademie, DocCheck, DocFlix, EAS, GSK und Novartis. Sie erh\u00e4lt Forschungsf\u00f6rderungen vom Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt (BMFTR), vom Bundesministerium f\u00fcr Wirtschaft und Klimaschutz (BMWK), von der Deutschen Krebshilfe, vom Deutschen Zentrum f\u00fcr Herz- und Kreislauf-Forschung (DZHK), vom Deutschen Zentrum f\u00fcr Diabetesforschung (DZD) und von der Deutschen Herzstiftung. Es bestehen keine Besch\u00e4ftigungsverh\u00e4ltnisse zu gewinnorientierten oder gemeinn\u00fctzigen Organisationen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}